000			01798 a2200493 4500
005			20250513211706.0
264		0	_c20000908
008			200009s 0 0 eng d
022			_a0143-3636
024	7		_a10.1097/00006231-200003000-00010 _2doi
040			_aNLM _beng _cNLM
100	1		_aKällén, K
245	0	0	_aQuantitative 201Tl SPET imaging in the follow-up of treatment for brain tumour: a sensitive tool for the early identification of response to chemotherapy? _h[electronic resource]
260			_bNuclear medicine communications _cMar 2000
300			_a259-67 p. _bdigital
500			_aPublication Type: Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aAstrocytoma _xdiagnostic imaging
650	0	4	_aBrain Neoplasms _xdiagnostic imaging
650	0	4	_aFemale
650	0	4	_aFollow-Up Studies
650	0	4	_aHumans
650	0	4	_aLomustine _xtherapeutic use
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aProcarbazine _xtherapeutic use
650	0	4	_aProspective Studies
650	0	4	_aRadiopharmaceuticals
650	0	4	_aSurvival Analysis
650	0	4	_aThallium Radioisotopes
650	0	4	_aTime Factors
650	0	4	_aTomography, Emission-Computed, Single-Photon
650	0	4	_aTomography, X-Ray Computed
650	0	4	_aVincristine _xtherapeutic use
700	1		_aGeijer, B
700	1		_aMalmström, P
700	1		_aAndersson, A M
700	1		_aHoltås, S
700	1		_aRyding, E
700	1		_aRosén, I
773	0		_tNuclear medicine communications _gvol. 21 _gno. 3 _gp. 259-67
856	4	0	_uhttps://doi.org/10.1097/00006231-200003000-00010 _zAvailable from publisher's website
999			_c10774924 _d10774924